MART-1–Specific Melanoma Tumor-Infiltrating Lymphocytes Maintaining CD28 Expression Have Improved Survival and Expansion Capability Following Antigenic Restimulation In Vitro
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
We determined how CD8+ melanoma tumor–infiltrating lymphocytes (TILs) isolated from two distinct phases of expansion in preparation for adoptive T cell therapy respond to melanoma Ag restimulation. We found that TILs isolated after the rapid expansion protocol (REP) phase, used to generate the final patient TIL infusion product, were hyporesponsive to restimulation with MART-1 peptide-pulsed dendritic cells, with many CD8+ T cells undergoing apoptosis. Telomere length was shorter post-REP, but of sufficient length to support further cell division. Phenotypic analysis revealed that cell-surface CD28 expression was significantly reduced in post-REP TILs, whereas CD27 levels remained unchanged. Tracking post-REP TIL proliferation by CFSE dilution, as well as sorting for CD8+CD28+ and CD8+CD28− post-REP subsets, revealed that the few CD28+ TILs remaining post-REP had superior survival capacity and proliferated after restimulation with MART-1 peptide. An analysis of different supportive cytokine mixtures during the REP found that a combination of IL-15 and IL-21 facilitated comparable expansion of CD8+ TILs as IL-2, but prevented the loss of CD28 expression with improved responsiveness to antigenic restimulation post-REP. These results suggest that current expansion protocols using IL-2 for melanoma adoptive T cell therapy yields largely CD8+ T cells unable to persist and divide in vivo following Ag contact. The few CD8+CD28+ T cells that remain may be the only CD8+ TILs that ultimately survive to repopulate the host and mediate long-term tumor control. A REP protocol using IL-15 and IL-21 may greatly increase the number of CD28+ TILs capable of long-term persistence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Central Memory and Effector Memory T Cell Subsets: Function, Generation, and Maintenance
Sallusto, F., Geginat, J., & Lanzavecchia, A. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104702 · Cited by 3,067
Cancer regression in patients after transfer of genetically engineered lymphocytes
Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006) · Science · doi:10.1126/science.1129003 · Cited by 2,603 · cited 2×
“MART-1– reactive T cells can also mount effective antitumor responses during ACT in patients (9, 11, 24).”
BackgroundMethodMonteiro, J., Batliwalla, F., Ostrer, H., & Gregersen, P. K. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.10.3587 · Cited by 376 · cited 1×
“CD28(2) T cells have been found to have decreased telomere lengths, and this has been associated with lack of proliferative ability and persistence in vivo (34, 35).”
BackgroundPalmer, L. D., Weng, N.-P., Levine, B. L., June, C. H., Lane, H. C., & Hodes, R. J. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.7.1381 · Cited by 129 · cited 1×
“CD28(2) T cells have been found to have decreased telomere lengths, and this has been associated with lack of proliferative ability and persistence in vivo (34, 35).”
Background
Cited by
Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent
Kamphorst, A. O., Wieland, A., Nasti, T., Yang, S., Zhang, R., Barber, D. L., Konieczny, B. T., Daugherty, C. Z., Koenig, L., Yu, K., et al. (2017) · Science · doi:10.1126/science.aaf0683 · Cited by 1,015
“Confirming previous reports (19, 20), we found variable CD28 expression, ranging from 20 to 90% of the CD8 tumor infiltrating lymphocyte (TIL) population, in individual NSCLC patient samples (Fig.”
BackgroundResultChromatin states define tumour-specific T cell dysfunction and reprogramming
Philip, M., Fairchild, L., Sun, L., Horste, E. L., Camara, S., Shakiba, M., Scott, A. C., Viale, A., Lauer, P., Merghoub, T., et al. (2017) · Nature · doi:10.1038/nature22367 · Cited by 933
Azimi, F., Scolyer, R. A., Rumcheva, P., Moncrieff, M., Murali, R., McCarthy, S. W., Saw, R. P., & Thompson, J. F. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.8539 · Cited by 856
Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1-CD8+ Tumor-Infiltrating T Cells
Kurtulus, S., Madi, A., Escobar, G., Klapholz, M., Nyman, J., Christian, E., Pawlak, M., Dionne, D., Xia, J., Rozenblatt-Rosen, O., et al. (2019) · Immunity · doi:10.1016/j.immuni.2018.11.014 · Cited by 636
Role of IL-2 in cancer immunotherapy
Jiang, T., Zhou, C., & Ren, S. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1163462 · Cited by 549
Metadata
- Authors
- Li, Y., Liu, S., Hernandez, J., Vence, L., Hwu, P., & Radvanyi, L.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-12-14
- Volume
- 184
- Issue
- 1
- Pages
- 452-465
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1736513025
- Cited by
- 97
- References
- 4
- FWCI
- 2.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: MART-1–Specific Melanoma Tumor-Infiltrating Lymphocytes Maintaining CD28 Expression Have Improved Survival and Expansion Capability Following Antigenic Restimulation In Vitro. https://app.cochat.ai/papers/10.4049/jimmunol.0901101
- The paper
- Li, Y., Liu, S., Hernandez, J., Vence, L., Hwu, P., & Radvanyi, L. (2010). MART-1–Specific Melanoma Tumor-Infiltrating Lymphocytes Maintaining CD28 Expression Have Improved Survival and Expansion Capability Following Antigenic Restimulation In Vitro. The Journal of Immunology. https://doi.org/10.4049/jimmunol.0901101
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.